Trial watch: BTK inhibitor shows positive results in B cell malignancies

@article{Harrison2012TrialWB,
  title={Trial watch: BTK inhibitor shows positive results in B cell malignancies},
  author={Charlotte Harrison},
  journal={Nature Reviews Drug Discovery},
  year={2012},
  volume={11},
  pages={96-97}
}
Preliminary clinical trial data recently presented at the American Society of Hematology meeting showed that the Bruton’s tyrosine kinase (BTK) inhibitor PCI‐32765 was effective in treating in several types of B cell lymphoma. Furthermore, PCI‐32765 is at the centre of a deal — worth up to US$975 million — between the drug’s developer Pharmacyclics and Janssen Biotech. “BTK is involved in signal transduction in the B cell receptor signalling pathway,” explains Simon Rule, a consultant… CONTINUE READING